Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1W50M | ISIN: US31189P1021 | Ticker-Symbol: F6T
Tradegate
06.06.25 | 21:53
1,409 Euro
+0,46 % +0,007
1-Jahres-Chart
FATE THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
FATE THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,4001,46006.06.
1,3901,42706.06.

Aktuelle News zur FATE THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFATE THERAPEUTICS INC - S-8, Securities to be offered to employees in employee benefit plans1
30.05.FATE THERAPEUTICS INC - 8-K, Current Report2
30.05.Fate Therapeutics beruft neues Vorstandsmitglied6
30.05.Fate Therapeutics appoints new board member1
30.05.Fate Therapeutics, Inc.: Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors1
29.05.Fate Therapeutics to present lupus treatment data at EULAR 20253
29.05.Fate Therapeutics, Inc.: Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress3
FATE THERAPEUTICS Aktie jetzt für 0€ handeln
14.05.Fate Therapeutics' Q1 Earnings & Revenues Beat, Pipeline in Focus5
14.05.Baird cuts Fate Therapeutics stock target to $4, keeps neutral rating2
13.05.Fate Therapeutics, Inc.: Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates132Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June ...
► Artikel lesen
13.05.FATE THERAPEUTICS INC - 8-K, Current Report1
02.05.Fate Therapeutics, Inc.: Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)86SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent...
► Artikel lesen
29.04.Fate Therapeutics, Inc.: Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting3
15.04.Fate Therapeutics' Lupus Candidate FT819 Gets FDA RMAT Tag21
14.04.Fate Therapeutics gets RMAT status from FDA for Lupus treatment4
14.04.FDA beschleunigt Zulassungsverfahren für neue CAR-T-Zelltherapie von Fate Therapeutics11
14.04.Fate Therapeutics' new CAR T-cell therapy fast-tracked by FDA4
14.04.Fate Therapeutics, Inc.: Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)225- Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the development process - RMAT review by FDA included...
► Artikel lesen
06.03.Stifel cuts Fate Therapeutics stock target to $3, maintains hold1
06.03.Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating7
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1